A new study published in Arthritis Care and Research found that mandatory switching policies were much more effective at driving biosimilar uptake than new start policies. The study examined 5,884 patients taking infliximab (Johnson & Johnson’s Remicade®, Pfizer’s Inflectra®, Organon’s Renflexis®) or etanercept (Amgen’s Enbrel®, Samsung Bioepis’ Brenzys®, Sandoz’ Erelzi®) and found that after the switching policy there was a sustained increase in the proportion of dispensed biosimilar etanercept and infliximab prescriptions and a persistent increase in monthly spending on the biosimilars
We recently reported on a study that found that British Columbia’s Biosimilars Initiative did not negatively impact patients.